Korean Journal of Veterinary Research (대한수의학회지)

The Korean Society of Veterinary Science (대한수의학회)
권호 표지
DOI QR코드

DOI QR Code

Antiviral effect of 18-mer-peptide (1b-4/21-C12) on Japanese encephalitis virus and Akabane virus

  • Yang, Dong-Kun (Viral Disease Division, Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs (MAFRA)) ;
  • Park, Yu-Ri (Viral Disease Division, Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs (MAFRA)) ;
  • Kwon, Young Do (R&D Institute, Daehan Nupharm) ;
  • Kim, Ha-Hyun (Viral Disease Division, Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs (MAFRA)) ;
  • Hyun, Bang-Hun (Viral Disease Division, Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs (MAFRA))
  • Received : 2022.05.09
  • Accepted : 2022.06.24
  • Published : 2022.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Japanese encephalitis virus (JEV) and Akabane virus (AKAV) are mosquito-borne viruses that cause encephalitis and reproductive disorders in horses and cattle, respectively. There is no treatment for JEV or AKAV infections in animals. Therefore, we evaluated the antiviral activity of 18-mer amphipathic peptides in the 1b-4/21-C series on JEV and AKAV using Vero cells in vitro and evaluated their effects on JEV in mice. Of 6 peptides, 1b-4/21-C12 had the lowest IC50 of 0.313 against JEV and its use as an antiviral against JEV and AKAV was examined. The IC50 of 1b-4/21-C12 against JEV and AKAV was 0.78 and 1.14 µM, respectively. Mice treated with 5 or 2 mg/kg of 1b-4/21-C12 had 32% and 16% survival rates, respectively, and the surviving mice treated with 1b-4/21-C12 began to gain weight beginning 8 days post challenge with the virulent Nakayama strain. Moreover, 20 µM 1b-4/21-C peptide had no cytotoxic effects on Vero cells. Our in vitro and in vivo results indicate that 1b-4/21-C12 has antiviral activity against enveloped JEV and AKAV and might be useful as a therapeutic substance.

Keywords

Acknowledgement

This work was supported financially by a grant (121005-1) from Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET), Ministry of Agriculture, Food and Rural Affairs (MAFRA), Republic of Korea.

References

  1. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011;89:766-774. https://doi.org/10.2471/BLT.10.085233
  2. Lee EJ, Cha GW, Ju YR, Han MG, Lee WJ, Jeong YE. Prevalence of neutralizing antibodies to japanese encephalitis virus among high-risk age groups in South Korea, 2010. PLoS One 2016;11:e0147841. https://doi.org/10.1371/journal.pone.0147841
  3. Yang DK, Nah JJ, Kim HH, Song JY. Inactivated genotype 1 Japanese encephalitis vaccine for swine. Clin Exp Vaccine Res 2014;3:212-219. https://doi.org/10.7774/cevr.2014.3.2.212
  4. Tang HB, Ren P, Qin S, Lin J, Bai A, Qin S, Chen F, Liu J, Wu J. Isolation, genetic analysis of the first Akabane virus from goat in China. J Vet Med Sci 2019;81:1445-1449. https://doi.org/10.1292/jvms.18-0602
  5. Golender N, Bumbarov V, Kovtunenko A, David D, Guini-Rubinstein M, Sol A, Beer M, Eldar A, Wernike K. Identification and genetic characterization of viral pathogens in ruminant gestation abnormalities, Israel, 2015-2019. Viruses 2021;13:2136. https://doi.org/10.3390/v13112136
  6. Yanase T, Hayama Y, Shirafuji H, Tsutsui T, Terada Y. Surveillance of Culicoides biting midges in northern Honshu, Japan, during the period of Akabane virus spread. J Vet Med Sci 2019;81:1496-1503. https://doi.org/10.1292/jvms.19-0303
  7. Oem JK, Lee KH, Kim HR, Bae YC, Chung JY, Lee OS, Roh IS. Bovine epizootic encephalomyelitis caused by Akabane virus infection in Korea. J Comp Pathol 2012;147:101-105. https://doi.org/10.1016/j.jcpa.2012.01.013
  8. Yang DK, Kim HH, Jo HY, Choi SS, Cho IS. Development of inactivated Akabane and bovine ephemeral fever vaccine for cattle. Korean J Vet Res 2015;55:227-232. https://doi.org/10.14405/kjvr.2015.55.4.227
  9. Han SR, Lee SW. Inhibition of Japanese encephalitis virus (JEV) replication by specific RNA aptamer against JEV methyltransferase. Biochem Biophys Res Commun 2017;483:687-693. https://doi.org/10.1016/j.bbrc.2016.12.081
  10. Sebastian L, Desai A, Shampur MN, Perumal Y, Sriram D, Vasanthapuram R. N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo. Virol J 2008;5:64. https://doi.org/10.1186/1743-422X-5-64
  11. Fan W, Qian S, Qian P, Li X. Antiviral activity of luteolin against Japanese encephalitis virus. Virus Res 2016;220:112-116. https://doi.org/10.1016/j.virusres.2016.04.021
  12. Lien JC, Wang CY, Lai HC, Lu CY, Lin YF, Gao GY, Chen KC, Huang AC, Huang SH, Lin CW. Structure analysis and antiviral activity of CW-33 analogues against Japanese encephalitis virus. Sci Rep 2018;8:16595. https://doi.org/10.1038/s41598-018-34932-4
  13. Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W. Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. Antiviral Res 2017;141:140-149. https://doi.org/10.1016/j.antiviral.2017.02.009
  14. Wei J, Hameed M, Wang X, Zhang J, Guo S, Anwar MN, Pang L, Liu K, Li B, Shao D, Qiu Y, Zhong D, Zhou B, Ma Z. Antiviral activity of phage display-selected peptides against Japanese encephalitis virus infection in vitro and in vivo. Antiviral Res 2020;174:104673. https://doi.org/10.1016/j.antiviral.2019.104673
  15. Jiang S, Lin K, Strick N, Neurath AR. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. Biochem Biophys Res Commun 1993;195:533-538. https://doi.org/10.1006/bbrc.1993.2078
  16. Jackman JA, Costa VV, Park S, Real ALCV, Park JH, Cardozo PL, Ferhan AR, Olmo IG, Moreira TP, Bambirra JL, Queiroz VF, Queiroz-Junior CM, Foureaux G, Souza DG, Ribeiro FM, Yoon BK, Wynendaele E, De Spiegeleer B, Teixeira MM, Cho NJ. Therapeutic treatment of Zika virus infection using a brain-penetrating antiviral peptide. Nat Mater 2018;17:971-977. https://doi.org/10.1038/s41563-018-0194-2
  17. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938;27:493-497.
  18. Jackman JA, Saravanan R, Zhang Y, Tabaei SR, Cho NJ. Correlation between membrane partitioning and functional activity in a single lipid vesicle assay establishes design guide-lines for antiviral peptides. Small 2015;11:2372-2379. https://doi.org/10.1002/smll.201403638
  19. Yuan S, Chan JF, Ye ZW, Wen L, Tsang TG, Cao J, Huang J, Chan CC, Chik KK, Choi GK, Cai JP, Yin F, Chu H, Liang M, Jin DY, Yuen KY. Screening of an FDA-approved drug library with a two-tier system identifies an entry inhibitor of severe fever with thrombocytopenia syndrome virus. Viruses 2019; 11:385. https://doi.org/10.3390/v11040385
  20. Sebastian L, Desai A, Yogeeswari P, Sriram D, Madhusudana SN, Ravi V. Combination of N-methylisatin-β-thiosemicarbazone derivative (SCH16) with ribavirin and mycophenolic acid potentiates the antiviral activity of SCH16 against Japanese encephalitis virus in vitro. Lett Appl Microbiol 2012;55: 234-239. https://doi.org/10.1111/j.1472-765X.2012.03282.x
  21. Schoenenwald AKJ, Gwee CP, Stiasny K, Hermann M, Vasudevan SG, Skern T. Development and characterization of specific anti-Usutu virus chicken-derived single chain variable fragment antibodies. Protein Sci 2020;29:2175-2188. https://doi.org/10.1002/pro.3937
  22. Wang S, Liu Y, Guo J, Wang P, Zhang L, Xiao G, Wang W. Screening of FDA-approved drugs for inhibitors of Japanese encephalitis virus infection. J Virol 2017;91:e01055-17